Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab versus placebo in retreated intravenous steroid‑refractory ulcerative colitis
2005-003481-42Phase 2Terminated
- Sponsor
- PDL BioPharma
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Visilizumab retreatment with Placebo (2 arms). Primary endpoint: Retreatment clinical response at Day 45 for first retreatment course. Started Nov 2005; status: terminated.
02
Drugs
visilizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2005-003481-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003481-42.